Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:MRX Medicis Pharmaceutical (MRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesOptions ChainTrends About Medicis Pharmaceutical Stock (NYSE:MRX) 30 days 90 days 365 days Advanced Chart Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Medicis Pharmaceutical alerts:Sign Up Key Stats Today's Range$25.00▼$25.6950-Day Range N/A52-Week Range N/AVolume279,694 shsAverage Volume211,322 shsMarket Capitalization$1.80 billionP/E RatioN/ADividend Yield2.20%Price Target$27.00Consensus RatingBuy Company OverviewMedicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Medicis Pharmaceutical Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks3rd Percentile Overall ScoreMRX MarketRank™: Medicis Pharmaceutical scored higher than 3% of companies evaluated by MarketBeat, and ranked 930th out of 933 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingMedicis Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedicis Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Medicis Pharmaceutical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Medicis Pharmaceutical are expected to remain at $2.80 per share in the coming year.Read more about Medicis Pharmaceutical's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MRX. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldMedicis Pharmaceutical pays a meaningful dividend of 2.41%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthMedicis Pharmaceutical does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Medicis Pharmaceutical will have a dividend payout ratio of 20.00% next year. This indicates that Medicis Pharmaceutical will be able to sustain or increase its dividend.Read more about Medicis Pharmaceutical's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MRX. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Medicis Pharmaceutical this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for MRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medicis Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.79% of the stock of Medicis Pharmaceutical is held by insiders.Read more about Medicis Pharmaceutical's insider trading history. Receive MRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address MRX Stock News HeadlinesMarex Expands in the Middle East with the Acquisition of Aarna CapitalOctober 2, 2024 | globenewswire.comMarex Acquires Biofuels Company DropetOctober 1, 2024 | globenewswire.com625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.October 8, 2024 | Crypto Swap Profits (Ad)Key Carbon & Marex Group Announce Carbon Financing and InvestmentSeptember 26, 2024 | globenewswire.comMarex Group plc to participate in upcoming Barclays Global Financial Services ConferenceSeptember 6, 2024 | globenewswire.comMRX Stock Earnings: Marex Group Beats EPS, Beats Revenue for Q2 2024August 25, 2024 | investorplace.comWhy Marex Group Stock Was Skyrocketing This WeekAugust 16, 2024 | fool.comMarex Group plc announces 2024 Interim ResultsAugust 14, 2024 | globenewswire.comSee More Headlines MRX Stock Analysis - Frequently Asked Questions How were Medicis Pharmaceutical's earnings last quarter? Medicis Pharmaceutical Corp (NYSE:MRX) announced its quarterly earnings data on Wednesday, August, 14th. The healthcare company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of $0.53 by $0.37. The business's revenue for the quarter was up 15.4% on a year-over-year basis. When did Medicis Pharmaceutical IPO? Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering (IPO) on Thursday, April 25th 2024. The company issued 15,384,615 shares at a price of $19.00 per share. When does the company's lock-up period expire? Medicis Pharmaceutical's lock-up period expires on Tuesday, October 22nd. Medicis Pharmaceutical had issued 15,384,615 shares in its initial public offering on April 25th. The total size of the offering was $292,307,685 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. Company Calendar Last Earnings8/14/2024Ex-Dividend for 9/16 Dividend8/30/2024Dividend Payable9/16/2024Today10/08/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry Security & commodity brokers, dealers, exchanges & services Sub-IndustryN/A Current SymbolNYSE:MRX CUSIPN/A CIK859368 Webwww.Medicis.com Phone+1-212-5992000FaxN/AEmployees2,074Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$33.00 Low Stock Price Target$24.00 Potential Upside/Downside+6.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.18 Current Ratio1.09 Quick Ratio1.08 Sales & Book Value Annual Sales$1.24 billion Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares70,820,000Free Float68,134,000Market Cap$1.80 billion OptionableOptionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:MRX) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicis Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRX Stock Alerts